Clinical trial
Vorinostat and Temozolomide in Treating Patients With Malignant Gliomas
NCT00268385 · National Cancer Institute (NCI), NIH · Active, not recruiting
Key facts
| NCT number | NCT00268385 |
|---|---|
| Title | Vorinostat and Temozolomide in Treating Patients With Malignant Gliomas |
| Official title | A Phase I Study of Vorinostat (Suberoylanilide Hydroxamic Acid [SAHA]) in Combination With Temozolomide in Patients With Malignant Gliomas |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Active, not recruiting |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Adult Mixed Glioma, Recurrent Adult Brain Neoplasm |
| Intervention type | Drug, Other |
| Interventions | Laboratory Biomarker Analysis, Pharmacological Study, Temozolomide, Vorinostat |
| Enrollment | 83 |
| Start date | Dec 16, 2005 |
| Primary completion | Oct 18, 2018 |
| Completion | Apr 24, 2026 |
| First posted | Dec 22, 2005 |
| Last update posted | Aug 21, 2025 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: